Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin.

Muresanu DF, Rainer M, Moessler H

Journal of neural transmission. Supplementum1 Jan 2002Cited by 11 (Europe PMC)

PMID12456070DOI10.1007/978-3-7091-6139-5_25PepBankPUB-12456070

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In Alzheimer's disease patients, Cerebrolysin improved cognitive function after therapy in a placebo-controlled study.
In plain wordsIn Alzheimer's disease patients, Cerebrolysin improved thinking after therapy in a placebo-controlled study.
Peptide
Cerebrolysin
Outcome
IncreaseCognitive function
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 ml · infusion · six consecutive weeksAs given in this study (human).
Source sentences
Summary
Significant improvement of cognitive function, clinical global impression and activities of daily living were seen after the end of the therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients received infusions of 30 ml Cere or placebo five days/week for six consecutive weeks.
Summary · context
Patients had to have a diagnosis of AD and a MMSE score of 14-25 inclusive.
Report a problemFND-1245607001
02HumanNon-randomized trialEfficacy outcome
In Alzheimer's disease patients, Cerebrolysin improved clinical global impression after therapy in a placebo-controlled study.
In plain wordsIn Alzheimer's disease patients, Cerebrolysin improved overall clinical status after therapy in a placebo-controlled study.
Peptide
Cerebrolysin
Outcome
IncreaseClinical global impression
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 ml · infusion · six consecutive weeksAs given in this study (human).
Source sentences
Summary
Significant improvement of cognitive function, clinical global impression and activities of daily living were seen after the end of the therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients received infusions of 30 ml Cere or placebo five days/week for six consecutive weeks.
Summary · context
Patients had to have a diagnosis of AD and a MMSE score of 14-25 inclusive.
Report a problemFND-1245607002
03HumanNon-randomized trialEfficacy outcome
In Alzheimer's disease patients, Cerebrolysin improved daily activities after therapy, with the strongest effects on DAD scores.
In plain wordsIn Alzheimer's disease patients, Cerebrolysin improved daily activities after therapy in a placebo-controlled study.
Peptide
Cerebrolysin
Outcome
IncreaseActivities of daily living
Study
n: not reported in source
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
30 ml · infusion · six consecutive weeksAs given in this study (human).
Source sentences
Summary
Significant improvement of cognitive function, clinical global impression and activities of daily living were seen after the end of the therapy.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects were most pronounced in the DAD score, a measure for the capability to perform activities of daily living.
Summary · context
Patients received infusions of 30 ml Cere or placebo five days/week for six consecutive weeks.
Summary · context
Patients had to have a diagnosis of AD and a MMSE score of 14-25 inclusive.
Report a problemFND-1245607003
04HumanNon-randomized trialEfficacy outcome
In Alzheimer's disease patients, the Cerebrolysin treatment effect persisted after treatment cessation through week 18.
In plain wordsIn Alzheimer's disease patients, the Cerebrolysin treatment effect persisted after treatment stopped through week 18.
Peptide
Cerebrolysin
Outcome
IncreasePersistence of treatment effect
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 ml · infusion · six consecutive weeksAs given in this study (human).
Source sentences
Summary
Interestingly, and in line with the findings of earlier studies, the treatment effect of Cere was maintained after cessation of treatment up to the week 18 assessment.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients received infusions of 30 ml Cere or placebo five days/week for six consecutive weeks.
Summary · context
Patients had to have a diagnosis of AD and a MMSE score of 14-25 inclusive.
Report a problemFND-1245607004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.